Search
Danaher Corp
DHRAdd to Watchlist
171.160USD
-4.500-2.56%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
121.14BMarket Cap
32.96P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-2.56%
5 Days
-2.28%
1 Month
-12.76%
6 Months
-18.47%
Year to Date
-25.23%
1 Year
-12.14%
TradingKey Stock Score of Danaher Corp
Currency: USD Updated: 2026-05-08Key Insights
Danaher Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 247.57.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Danaher Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Danaher Corp Highlights
StrengthsRisks
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 20.13%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 20.13%.
Undervalued
The company’s latest PE is 32.96, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 597.30M shares, decreasing 0.04% quarter-over-quarter.
Held by Manning & Napier Group, LLC
Star Investor Manning & Napier Group, LLC holds 58.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.06.
Analyst Rating
Based on
26
analysts
Buy
Current Rating
247.571
Target Price
+42.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Danaher Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Danaher Corp Info
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Ticker SymbolDHR
CompanyDanaher Corp
CEOBlair (Rainer M)
Websitehttps://www.danaher.com/
Related Instruments
+2.77%
-1.99%
-0.76%
-3.09%
+3.65%
-2.98%
-2.32%
+1.44%
+1.38%
-4.67%
+1.42%
-5.59%
+2.12%
-3.38%
-2.11%
-2.50%
+1.32%
+11.27%
-2.55%Popular Instruments
92.193
-2.977 (-3.13%)
293.320
+5.880 (+2.05%)
215.200
+3.700 (+1.75%)
4714.280
+29.030 (+0.62%)
480.000
+16.090 (+3.47%)
1562.340
+222.380 (+16.60%)
746.810
+100.180 (+15.49%)
400.800
+2.810 (+0.71%)
80345.580
+242.490 (+0.30%)
428.350
+16.560 (+4.02%)
